Media Articles Related to Riastap (Fibrinogen Human)
Pradaxa Blood Thinner May Beat Warfarin After Bleeding Episode: Study
Source: MedicineNet Heart Attack Specialty [2016.12.02]
Title: Pradaxa Blood Thinner May Beat Warfarin After Bleeding Episode: Study
Category: Health News
Created: 12/1/2016 12:00:00 AM
Last Editorial Review: 12/2/2016 12:00:00 AM
Cangrelor Sans GPI Safe in PCI, With Less Bleeding (CME/CE)
Source: MedPage Today Cardiology [2016.12.01]
(MedPage Today) -- Only TIMI bleeds differed from Plavix-GPI combo in meta-analysis
Bleeding During Pregnancy (First Trimester)
Source: MedicineNet Ectopic Pregnancy Specialty [2016.11.30]
Title: Bleeding During Pregnancy (First Trimester)
Category: Diseases and Conditions
Created: 9/26/2013 12:00:00 AM
Last Editorial Review: 11/30/2016 12:00:00 AM
Drug Combo for Irregular Heartbeat Might Raise Bleeding Risk
Source: MedicineNet Atrial Fibrillation Specialty [2016.11.22]
Title: Drug Combo for Irregular Heartbeat Might Raise Bleeding Risk
Category: Health News
Created: 11/21/2016 12:00:00 AM
Last Editorial Review: 11/22/2016 12:00:00 AM
Bleeding Ulcer Symptoms and Causes
Source: MedicineNet Anemia Specialty [2016.11.10]
Title: Bleeding Ulcer Symptoms and Causes
Category: Doctor's & Expert's views on Symptoms
Created: 4/3/2009 12:00:00 AM
Last Editorial Review: 11/10/2016 12:00:00 AM
Published Studies Related to Riastap (Fibrinogen Human)
Intraarticular fibrinogen does not reduce blood loss in TKA: a randomized
clinical trial. 
after surgery... CONCLUSIONS: The use of fibrinogen in TKA did not lead to a significant reduction
An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with
chronic obstructive pulmonary disease. 
The aims were to determine the effect of an oral inhibitor of the signaling
mediator p38 mitogen-activated protein kinase (GW856553, losmapimod) on sputum
neutrophils, pulmonary function, and blood biomarkers of inflammation in chronic
obstructive pulmonary disease (COPD)... It was
concluded that oral losmapimod significantly reduced plasma fibrinogen in
patients with COPD.
The fibrinogen cleavage product Aalpha-Val360, a specific marker of neutrophil elastase activity in vivo. [2011.08]
BACKGROUND: Alpha-1-antitrypsin (A1AT) deficiency is the only recognised genetic risk factor for chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and mortality worldwide. Since A1AT is the major inhibitor of neutrophil elastase (NE), this enzyme has become widely implicated in the pathogenesis of COPD in general; however, there is currently no specific biomarker for its pre-inhibition activity. Such a biomarker should be a measure of elastase-specific COPD disease activity with the potential to assess early targeted therapeutic intervention, in contrast to traditional and non-specific disease severity markers such as forced expiratory volume in 1 s... CONCLUSIONS: Aalpha-Val(360) represents the first specific footprint of pre-inhibition NE activity and is a potential biomarker of disease activity and progression in subjects with elastase-dependent COPD. TRIAL REGISTRATION: The EXACTLE study was registered in ClinicalTrials.gov as 'Antitrypsin (AAT) to Treat Emphysema in AAT-Deficient Patients'; ClinicalTrials.gov Identifier: NCT00263887.
De Marco Formula effectiveness as an adjunctive therapy to prevent infected ischemic diabetic foot amputation and reduce plasma fibrinogen. [2011.05]
BACKGROUND: De Marco Formula (DMF) is a new procaine chemical combination of Procaine HCl and polyvinylpyrrolidone. A prospective randomized controlled clinical trial demonstrated that infected ischemic diabetic foot treatment with DMF for 52 days as an adjuvant with conventional therapy reduced major amputations. OBJECTIVE: To evaluate the possible association of clinical effectiveness and plasma fibrinogen reduction with DMF therapy... CONCLUSION: DMF combined with conventional therapy for infected ischemic diabetic foot was associated with plasma fibrinogen decrease. Copyright (c) 2010 Tissue Viability Society. Published by Elsevier Ltd. All rights reserved.
Association between gamma' fibrinogen levels and inflammation. [2011.04]
The gamma' fibrinogen isoform produces clots that are stiffer and more resistant to breakdown than the more common fibrinogen isoform, gammaA. Increased levels of gamma' fibrinogen are associated with several forms of cardiovascular disease...
Clinical Trials Related to Riastap (Fibrinogen Human)
RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery [Terminated]
Heart surgery involving valve replacement often involves the use of the heart-lung machine
for over 90 minutes, and bleeding tendency is frequently seen. Conventionally, platelet
transfusion has been the primary therapy to treat bleeding after this type of procedure.
More recently, perioperative supplementation of purified fibrinogen (RiaSTAP, CSL Behring)
was shown to reduce bleeding and blood product use (plasma or platelets) after heart
surgery. The objective of this trial is to demonstrate the clinical equivalency and economic
utility of using fibrinogen concentrate, RiaSTAP for the mitigation of post-operative
bleeding in patients in lieu of platelet transfusion.
Purified fibrinogen concentrate has been approved by FDA, and it has been used for the
treatment of acute bleeding episodes in patients with low fibrinogen due to hereditary
causes (e. g., afibrinogenemia). Compared to the transfusion of platelets which may be
associated with volume overload, bacterial/viral infection, immunological effects and excess
blood clotting, purified fibrinogen has several advantages. First, it contains no liquid
plasma allowing for low volume infusion. Several viral inactivation/reduction steps are used
to prepare the fibrinogen concentrate, increasing its viral safety. No antibodies or white
blood cells are contained in the fibrinogen concentrate; therefore transfusion reactions are
rare. Although platelet transfusion is widely used after heart surgery, there has been no
randomized study to endorse this practice. In this study, patients undergoing heart valve
replacement will be randomized to receive either platelet (1 unit) transfusion or fibrinogen
concentrate (4g) after heparin anticoagulation is reversed. Subjects will be treated only if
there is evidence of significant microvascular bleeding. Fifteen minutes after the initial
treatment, subjects will be reevaluated for bleeding. If bleeding continues, subjects will
be treated with blood transfusion per institutional standard of care.
The primary endpoints for this study are the hemostatic condition of the surgical field and
24-hour total of blood product transfusion.
Pilot Randomized Trial of Fibrinogen in Trauma Haemorrhage [Recruiting]
Effect of immediate, pre-emptive fibrinogen concentrate in patients with trauma haemorrhage
needing haemostatic resuscitation - a randomized, controlled, double-blinded
investigator-initiated pilot trial
Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery [Recruiting]
The aim of the study is to show that first line treatment with concentrated fibrinogen has
superiority over the conventional therapy with fresh frozen plasma (FFP), platelets, and
cryoprecipitate in perioperative management of bleeding after complex cardiac surgery.
The Efficacy of the Administration of Fibrinogen in Liver Transplantation [Active, not recruiting]
- To evaluate the efficacy of preoperative administration of fibrinogen in liver
transplantation by maintaining a preoperative plasma level equal to 2. 9 g / L compared
with placebo, reflecting a reduction in the number of RBC units transfused during the
- To determine the influence of fibrinogen administration on mortality and survival of
liver graft evaluated one year after the procedure.
- To determine the safety of fibrinogen administration recording thrombotic complications
evaluated during hospitalization or at least 30 days postoperatively.
Human Fibrinogen - Pharmacokinetics [Completed]
This study evaluated the single-dose pharmacokinetics of human fibrinogen concentrate and
clot strength (maximum clot firmness [MCF]) in subjects with congenital fibrinogen
deficiency. MCF was measured to demonstrate the functional activity of replacement
fibrinogen when a fixed dose of human fibrinogen concentrate was administered.